

Comorbidities, mortality, and management of chronic obstructive pulmonary disease patients who required admissions to public hospitals in Hong Kong – computerized data collection and analysis

Hok Sum Chan¹
Fanny Wai San Ko²
Johnny Wai Man Chan³
Loletta Kit Ying So⁴
David Chi Leung Lam⁵
Veronica Lee Chan⁶
Cheuk Yin Tam⁷
Wai Cho Yu⁸

¹Department of Medicine, Alice Ho Miu Ling Nethersole Hospital,

²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, ³Department of Medicine, Queen Elizabeth Hospital,

⁴Department of Medicine, Pamela Youde Nethersole Eastern Hospital,

⁵Department of Medicine, Queen Mary Hospital, University of Hong Kong, ⁶Department of Medicine and Geriatrics, United Christian Hospital, ⁷Department of Medicine and Geriatrics, Tuen Mun Hospital,

⁸Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong

Background: COPD is a common cause for hospital admission. Conventional studies of the epidemiology of COPD involved large patient number and immense resources and were difficult to be repeated. The present study aimed at assessing the utilization of a computerized data management system in the collection and analysis of the epidemiological and clinical data of a large COPD cohort in Hong Kong (HK).

Patients and methods: It was a computerized, multicenter, retrospective review of the characteristics of patients discharged from medical departments of the 16 participating hospitals with the primary discharge diagnosis of COPD in 1 year (2012). Comparison was made between the different subgroups in the use of medications, ventilatory support, and other health care resources. The mortality of the subjects in different subgroups was traced up to December 31, 2014. The top 10 causes of death were analyzed.

Results: In total, 9,776 subjects (82.6% men, mean age = 78 years) were identified. Of the 1,918 subjects with lung function coding, 85 (4.4%), 488 (25.5%), 808 (42.1%), and 537 (28.0%) subjects had the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1, 2, 3, and 4 classes, respectively. Patients with higher GOLD classes had higher number of hospital admissions, longer hospital stay, increased usage of noninvasive mechanical ventilation (NIV), combinations of long-acting bronchodilators, and higher mortality. Of the 9,776 subjects, 2,278 (23.3%) received NIV, but invasive mechanical ventilation was uncommon (134 of 9,776 subjects [1.4%]); 4,427 (45.3%) subjects had died by the end of 2014. The top causes of death were COPD, pneumonia, lung cancer, and other malignancies.

Conclusion: Patients admitted to hospitals for COPD in HK had significant comorbidities, mortality, and imposed heavy burden on health care resources. It is possible to collect and analyze data of a large COPD cohort through a computerized system. Suboptimal coding of lung function results was observed, and underutilization of long-acting bronchodilators was common.

Keywords: noninvasive ventilation, medications, chronic effect of TB, GOLD classification, health care resources

Introduction

COPD is a common disease that imposes a high burden on health care resources worldwide.^{1,2} The prevalence of COPD varied from 11.4% to 26.1%.¹ In Hong Kong (HK), the prevalence rates of COPD in the elderly population aged ≥ 60 years were 25.9% and 12.4% based on two different definitions with different spirometric criteria

Correspondence: Hok Sum Chan
Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, 6/F, Block J, 11 Chuen On Road, Tai Po, NT, Hong Kong
Email chanhs@ha.org.hk

(postbronchodilator $FEV_1/FVC < 70\%$ or lower limit of normal range).³ In HK, the crude mortality rate of COPD was 29.1/100,000, while the crude hospitalization rate was 193/100,000 in 2005.⁴ COPD ranked second (to respiratory infections) as a respiratory cause for hospitalization and inpatient bed-days. In elderly subjects aged ≥ 75 years, the hospitalization rate for COPD was as high as 2,225/100,000.⁴ The economic burden of COPD on the society is enormous.^{5,6}

Previous studies gave information on the overall morbidity, mortality,⁴ and the prevalence of COPD in HK.^{3,7} COPD patients in HK were undertreated compared with those in other countries. For example, the use of inhaled long-acting anti-muscarinic agent (LAMA) in HK (3.9%) was much lower than that in the other countries.⁸ No large-scale study has looked into other details of COPD patients in HK.⁹ There was no information on the severity of illness of a large COPD cohort requiring hospital admission in HK and how much resources they require in terms of length of hospital stay, medications, noninvasive mechanical ventilation (NIV), and invasive mechanical ventilation (IMV). There was also little information on the outcome of these patients over time.

Detailed studies of a large population of COPD patients involve immense resources. Demographic data of the COPD patients, their severity of disease, comorbidities, use of health care resources, and mortality would be invaluable for health care planning to manage the disease in the public sector. In HK, almost 95% of the population relied on the Hospital Authority (HA) for hospital medical service. All patient admissions under the HA were computerized and recorded in the clinical management system (CMS), but additional diagnosis and procedure coding had to be performed by the attending physician. It is possible to perform data retrieval with the HA Clinical Data Analysis and Reporting System (CDARS) software program.^{10,11} A pilot study was carried out in one center in 2010.¹⁰ Patients with the principal discharge diagnosis of COPD were identified, and a computerized report of their demographic data and the use of medical resources was generated using CDARS. Some of the data still required manual capture and case record review. We have extended the study to include a large COPD cohort based entirely on the CDARS and without the need of individual patient record review. No additional research assistant had been employed for the purpose of this study.

Patients and methods

Study design and patient recruitment

This was a multicentered retrospective study of COPD patients discharged from the medical departments of

13 public regional hospitals and 3 chest hospitals of the HA in HK, during the period from 1 January to 31 December 2012. A list of participating hospitals is provided in the Supplementary material. This list included all except one public acute regional hospital (with 24-hour acute emergency service) and all except one chest hospital in HK from 2012 to 2014. Data retrieval was performed with the HA CDARS.^{10,11} All patients with the principal diagnosis of COPD (International Classification of Diseases [ICD] codes 491, 491.2, 491.21, 492, 492.8, and 496) on discharge in 2012 were included. The inclusion criteria were as follows: 1) aged >40 years; 2) principal discharge diagnosis of COPD (with ICD codes as described earlier); and 3) discharge from the medical departments of the respective hospitals. The exclusion criteria included the following: 1) aged ≤ 40 years and 2) patients discharged from specialties other than Department of Medicine.

Case record review and data entry of individual patients were not required. The group data that were retrieved by CDARS included the following: 1) demographic data; 2) total number of admissions for each subject between 1 January and 31 December 2012; 3) total length of hospital stay in 2012; 4) number of attendances at accident and emergency departments (A&E) and at specialist outpatient clinics (SOPCs); 5) coding of lung function tests and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification (ever performed, if available); 6) treatment modalities including acute NIV (ICD code 93.9) and IMV (ICD code 96.70, 96.71, and 96.72); 7) medications used including inhaled corticosteroids (ICSs), long-acting beta-agonists (LABA), LAMA, or their combinations; 8) comorbidities (including hypertension, ischemic heart disease, diabetes mellitus, chronic effects of tuberculosis [old TB], bronchiectasis, congestive heart failure, and asthma) that were coded in previous hospital admissions; 9) mortality of those recruited patients from 1 January, 2012, to 31 December, 2014; and 10) the cause of death estimated from the principal diagnosis for the episode of hospital discharge which ended up in death.

The data that require coding by physicians included the principal and secondary diagnosis, procedure coding, and lung function coding. Coding for lung function was not mandatory for the diagnosis coding of COPD. For patients with spirometry data available, the GOLD criteria of post-bronchodilator FEV_1/FVC ratio $< 70\%$ and $FEV_1\%$ predicted were used for the diagnosis and staging of COPD.¹²

The study was approved by the Clinical Research Ethics Committees of all the participating hospitals. As this was a retrospective study with no active intervention, patient

consent was not required by our Clinical Research Ethics Committees for research projects that involve only review of medical information. Furthermore, individual case record was not performed for this study. Only clinical data without patients' personal information were sent to the coinvestigators for analysis.

Statistical analysis

The CDARS provided simple statistical analysis with mean and SD of the whole group and subgroups defined by different parameters. Additional statistical evaluations, eg, comparisons between subgroups, were performed using the SPSS Version 22 software package (IBM Corporation, Armonk, NY, USA). Data were expressed as mean ± SD. Comparisons between two groups were made by using the χ^2 test for categorical data, and unpaired student *t*-tests were used for continuous data where appropriate. Different stages of GOLD classification were compared by one-way analysis of variance and the Games-Howell post hoc tests. To test for any trend across stages of GOLD classification, the χ^2 tests for linear trend were used for categorical data. All reported *p*-values were two-sided. A *p*-value <0.05 is considered statistically significant.

Results

Patient characteristics

There were a total of 9,776 patients with the principal diagnosis of COPD during the study period with a total of 19,795 hospitalization episodes. Table 1 shows the demographic characteristics of the subjects. The subjects were mostly elderly with a mean age of 78.0±9.4 years, and 82.6% were men; 1,918 subjects (19.6%) had lung function tests ever performed that was coded in the admissions in 2012, and 85 (4.4%), 488 (25.5 %), 808 (42.1%), and 537 (28.0%) of the 1,918 subjects with lung function coding had GOLD 1, 2, 3, and 4 classes, respectively. The lung function test might have been performed in 2012 or earlier. The version of CDARS in 2012 was not able to ascertain the year of lung function performed. Patients with GOLD 3 and 4 COPD were 3 years younger than those with GOLD 1 and 2 COPD (74.9 vs 77.8 years, *p*<0.001). The mean age of female patients (F) was higher than that of male patients (M) for the whole group, all GOLD classes and those without lung function coding (Table 1).

Use of health care resources

Table 2 shows the use of health care resources of the subjects including attendance at A&E and SOPC, number of hospital admissions, and use of NIV and IMV. The subjects had an

Table 1 Demographic characteristics of the subjects (obtained from the first admission within the year 2012) with or without lung function coding

Characteristics	All subjects	GOLD 1	GOLD 2	GOLD 3	GOLD 4	<i>p</i> -value	GOLD 1-4	No lung function coding	<i>p</i> -value	GOLD 1-2	GOLD 3-4	<i>p</i> -value
Number	9,776	85	488	808	537		1,918	7,858		573	1,345	
Male (%)	8,079 (82.6)	74 (87.1)	421 (86.3)	743 (92.0)	483 (89.9)	0.044	1,721 (89.7)	6,358 (80.9)	< 0.001	495 (86.4)	1,226 (91.2)	0.002
Age (years); mean (SD)	78.0 (9.4); M: 77.0 (9.2); F: 83.1 (8.4)	77.7 (10.8); M: 76.5 (10.8); F: 85.5 (6.6)	77.8 (8.2); M: 77.3 (8.0); F: 80.7 (8.9)	76.0 (8.3); M: 75.5 (8.3); F: 80.8 (6.4)	73.4 (8.6); M: 72.9 (8.3); F: 77.4 (10.3)	GOLD 1 vs 4, <i>p</i>=0.004 ; GOLD 2 vs 3, <i>p</i>=0.001 ; GOLD 2 vs 4 & 3 vs 4, <i>p</i><0.001	75.8 (8.6); M: 75.3 (8.5); F: 80.1 (8.7)	78.6 (9.4); M: 77.4 (9.3); F: 83.5 (8.3)	< 0.001	77.8 (8.7); M: 77.2 (8.5); F: 81.4 (8.8)	74.9 (8.5); M: 74.5 (8.4); F: 79.2 (8.6)	< 0.001
Number of hospital admission in 2012; mean (SD)	2.03 (2.00)	2.07 (3.03)	2.37 (2.34)	2.59 (2.50)	3.28 (2.97)	GOLD 1 vs 4, <i>p</i>=0.005 ; GOLD 2 vs 4 & 3 vs 4, <i>p</i><0.001	2.70 (2.65)	1.86 (1.77)	< 0.001	2.32 (2.46)	2.87 (2.72)	< 0.001

Notes: GOLD 1-2 = GOLD 1 + GOLD 2; GOLD 3-4 = GOLD 3 + GOLD 4; GOLD 1-4 = GOLD 1 + GOLD 2 + GOLD 3 + GOLD 4. Bold figures indicate statistically significant (*p*<0.05).

Abbreviations: F, female; GOLD, Global Initiative for Chronic Obstructive Lung Disease; M, male.

Table 2 Use of health care resources of subjects according to the GOLD classification

	All subjects	GOLD 1	GOLD 2	GOLD 3	GOLD 4	p-value	GOLD 1-4	No lung function coding	p-value	GOLD 1-2	GOLD 3-4	p-value
Number	9,776	85	488	808	537		1,918	7,858		573	1,345	
Number of A&E attendance/headcount; mean (SD)	3.8 (4.9)	5.8 (20.0)	4.1 (4.0)	4.2 (5.5)	4.4 (4.2)	NS	4.3 (6.3)	3.6 (4.4)	<0.001	4.3 (8.5)	4.3 (5.0)	0.944
Number of SOPC attendance/headcount; mean (SD)	2.5 (2.5)	2.4 (2.9)	2.8 (2.4)	3.1 (2.5)	3.2 (2.5)	GOLD 2 vs 4, p=0.031	3.0 (2.5)	2.3 (2.5)	<0.001	2.7 (2.5)	3.1 (2.5)	0.002
Number of hospital admissions/headcount; mean (SD)	2.0 (2.0)	2.1 (3.0)	2.4 (2.3)	2.6 (2.5)	3.3 (3.0)	GOLD 1 vs 4, p=0.005 ; GOLD 2 vs 4 & 3 vs 4, p<0.001	2.7 (2.7)	1.9 (1.8)	<0.001	2.3 (2.5)	2.9 (2.7)	<0.001
NIV support during acute admission; number (%)	2,278 (23.3)	17 (20)	146 (29.9)	291 (36.0)	309 (57.5)	<0.001	763 (39.8%)	1,515 (19.3%)	<0.001	163 (28.4%)	600 (44.6%)	<0.001
IMV support during acute admission number (%)	134 (1.4%)	2 (2.4)	7 (1.4)	13 (1.6)	15 (2.8)	0.211	37 (1.9%)	108 (1.4%)	0.072	9 (1.6%)	28 (2.1%)	0.456
Length of hospital stay/headcount in days; mean (SD)	12.3 (18.5)	9.72 (14.0)	13.74 (20.5)	17.46 (24.2)	23.49 (28.5)	GOLD 1 vs 3, 1 vs 4, 2 vs 4, 3 vs 4, p<0.001 ; GOLD 2 vs 3, p=0.017	17.9 (24.6)	11.00 (16.5)	<0.001	13.1 (19.7)	19.9 (26.2)	<0.001
COPD deaths in 2012; number (%)	503 (5.1%)	1 (1.2)	17 (3.5)	31 (3.8)	51 (9.5)	<0.001	100 (5.2)	403 (5.1)	0.88	18 (3.1)	82 (6.1)	0.008

Notes: GOLD 1-2 = GOLD 1 + GOLD 2; GOLD 3-4 = GOLD 3 + GOLD 4; GOLD 1-4 = GOLD 1 + GOLD 2 + GOLD 3 + GOLD 4. Bold figures indicate statistically significant ($p < 0.05$).

Abbreviations: A&E, accident and emergency departments; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IMV, invasive mechanical ventilation; NIV, noninvasive mechanical ventilation; NS, not significant; SOPC, specialist outpatient clinics.

average of 3.8 emergency department visits and an average of 2.0 hospitalizations during the year 2012. Increasing GOLD stages were associated with more hospital admissions, longer length of hospital stay, SOPC attendances, higher percentage of NIV use during hospitalizations, and higher mortality (in the same year and after 2 years). Overall, 2,278 of 9,776 (23.3%) subjects required NIV during admission, whereas 309 of 537 (57.5%) patients with GOLD 4 disease had been treated with NIV. The use of IMV was low among all GOLD classes (overall 1.4%). Compared with patients without lung function coding (n=7,858), patients with lung function coding (n=1,918) had more attendance at A&E and SOPC, more hospitalizations, longer hospital stay (17.9 vs 11.0 days, $p<0.001$), and more requirement of NIV (39.8% vs 19.3%, $p<0.001$).

Pharmacotherapy and GOLD class

Table 3 shows the pharmacotherapy for COPD among recruited subjects. Overall, 9.9% of subjects were on LABA alone, 1% on LAMA alone, and 33.6% on ICS alone; 16.4% on LABA and LAMA combination, 10.1% on ICS and LABA, and 3.4% on ICS with LAMA; and 10.5% on triple therapy with ICS, LABA, and LAMA. Among subjects with and without lung function coding, 79.6% and 44.3% of the subjects were on at least one long-acting bronchodilator (LAMA and/or LABA), respectively. Patients without lung function coding were more likely to be on ICS alone (37.8% vs 16.3%, $p<0.001$). With increasing severity of GOLD class, more subjects were on combination of LABA and LAMA with or without ICS.

Comorbidities and GOLD class

Table 4 shows the comorbidities of COPD subjects. In total, 5,923 subjects (60.6%) had at least one of the comorbidities listed (hypertension, ischemic heart disease, diabetes mellitus, old TB, bronchiectasis, congestive heart failure, and asthma). Hypertension and diabetes mellitus were more common in patients with GOLD 1 and 2 (41.5% and 16.6%, respectively) than in patients with GOLD 3 and 4 diseases (35.0% and 12.5%, respectively). Figure 1 shows the comorbidities of the subjects in relation to the GOLD class of lung function. Patients with lower GOLD classes were more likely to have hypertension ($p=0.001$), while patients with higher GOLD classes were more likely to have chronic effect of TB ($p=0.048$). There were no significant differences for ischemic heart disease, bronchiectasis, congestive heart failure, or asthma with different GOLD classes.

Table 3 Medications use of subjects according to the GOLD classification

	All subjects (n=9,776)	GOLD 1 (n=85)	GOLD 2 (n=488)	GOLD 3 (n=808)	GOLD 4 (n=537)	p-value	GOLD 1-4 (n=1,918)	No lung function coding (n=7,858)	p-value	GOLD 1-2 (n=573)	GOLD 3-4 (n=1,345)	p-value
Not on LABA/LAMA/ICS	1,483 (15.2%)	16 (18.8%)	35 (7.2%)	20 (2.5%)	8 (1.5%)	<0.001	79 (4.1%)	1,404 (17.9%)	<0.001	51 (8.9%)	28 (2.1%)	<0.001
LABA alone	965 (9.9%)	8 (9.4%)	73 (15.0%)	102 (12.6%)	39 (7.3%)	0.002	222 (11.6%)	743 (9.5%)	0.005	81 (14.1%)	141 (10.5%)	0.022
LAMA alone	93 (1.0%)	1 (1.2%)	5 (1.0%)	10 (1.2%)	10 (1.9%)	0.276	26 (1.4%)	67 (0.9%)	0.042	6 (1.0%)	20 (1.5%)	0.446
ICS alone	3,285 (33.6%)	32 (37.6%)	130 (26.6%)	123 (15.2%)	27 (5.0%)	<0.001	312 (16.3%)	2,973 (37.8%)	<0.001	162 (28.3%)	150 (11.2%)	<0.001
LABA + LAMA	1,605 (16.4%)	8 (9.4%)	110 (22.5%)	260 (32.2%)	243 (45.3%)	<0.001	621 (32.4%)	984 (12.5%)	<0.001	118 (20.6%)	503 (37.4%)	<0.001
ICS + LABA (without LAMA)	988 (10.1%)	11 (12.9%)	57 (11.7%)	71 (8.8%)	34 (6.3%)	0.001	173 (9.0%)	815 (10.4%)	0.078	68 (11.9%)	105 (7.8%)	0.004
ICS + LAMA (without LABA)	329 (3.4%)	3 (3.5%)	28 (5.7%)	60 (7.4%)	27 (5.0%)	0.96	118 (6.2%)	211 (2.7%)	<0.001	31 (5.4%)	87 (6.5%)	0.377
ICS + LABA + LAMA	1,028 (10.5%)	6 (7.1%)	50 (10.2%)	162 (20.0%)	149 (27.7%)	<0.001	367 (19.1%)	661 (8.4%)	<0.001	56 (9.8%)	311 (23.1%)	<0.001

Notes: GOLD 1-2 = GOLD 1 + GOLD 2; GOLD 3-4 = GOLD 3 + GOLD 4; GOLD 1-4 = GOLD 1 + GOLD 2 + GOLD 3 + GOLD 4. Bold figures indicate statistically significant ($p<0.05$).
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting beta-agonists; LAMA, long-acting anti-muscarinic agent.

Table 4 Comorbidities of subjects according to the GOLD classification

Comorbidities	All subjects (n=9,776)	GOLD 1-4 (n=1,918)	No lung function coding (n=7,858)	p-value	GOLD 1-2 (n=573)	GOLD 3-4 (n=1,345)	p-value
Hypertension	3,932 (40.2%)	709 (37.0%)	3,223 (41.0%)	0.001	238 (41.5%)	471 (35.0%)	0.007
Ischemic heart disease	1,106 (11.3%)	240 (12.5%)	866 (11.0%)	0.064	74 (12.9%)	166 (12.3%)	0.729
Diabetes mellitus	1,469 (15.0%)	263 (13.7%)	1,206 (15.3%)	0.72	95 (16.6%)	168 (12.5%)	0.017
Chronic effect of TB	877 (9.0%)	239 (12.5%)	638 (8.1%)	< 0.001	64 (11.2%)	175 (13.0%)	0.264
Bronchiectasis	738 (7.5%)	186 (9.7%)	552 (7.0%)	< 0.001	46 (8.0%)	140 (10.4%)	0.107
Congestive heart failure	1,359 (13.9%)	200 (10.4%)	1,159 (14.7%)	< 0.001	64 (11.2%)	136 (10.1%)	0.488
Asthma	342 (3.5%)	77 (4.0%)	265 (3.4%)	0.17	25 (4.4%)	52 (3.9%)	0.612

Notes: GOLD 1-2 = GOLD 1 + GOLD 2; GOLD 3-4 = GOLD 3 + GOLD 4; GOLD 1-4 = GOLD 1 + GOLD 2 + GOLD 3 + GOLD 4. Bold figures indicate statistically significant ($p < 0.05$).

Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; TB, tuberculosis.

Mortality and causes of death

The causes of death could only be retrieved by CDARS for patients who died in the HA hospitals. For patients who died outside the HA hospitals (including those who were certified dead at A&E), the identity of the patients could be retrieved from the death registry, but the cause of death could not be ascertained by the CDARS. For patients who died in the HA hospitals, 503 of 9,776 (5.1%) patients died in 2012 due to COPD (5.1%), while the total all-cause mortality was 1,585 of 9,776 (16.2%). Review of the cumulative all cause-mortality in the HA hospitals showed that 2,877 (29.4%) patients had died by the end of 2013 and 3,867 (39.6%) patients had died by the end of 2014 (Table 5). The top common causes of death were pneumonia (32.3%), COPD (30.1%), lung

cancer (6.3%), other malignancies (4.0%), and respiratory failure (3.9%). Death from ischemic heart disease (2.7%), heart failure (1.8%), and cerebrovascular accident (1.0%) accounted for 5.5% of deaths due to cardiovascular causes.

As on 31 December, 2014, 3,876 of 9,776 (39.6%) and 560 of 9,776 (5.7%) of patients had died in and outside the HA hospitals, respectively (Table 5). Of the 560 cases with death outside the HA hospitals, 397 (70.9%) patients were certified dead at A&E department. The total mortality rate was 4,427/9,776 (45.3%) as in December 2014. The mortality rate of patients with GOLD 4 disease (51.6%) was significantly higher than in all other GOLD classes. The overall mean ages at death were 80.5 years for men and 86.4 years for women, respectively, which were very close

Prevalence of comorbidities in COPD




Figure 1 Prevalence of comorbidities in COPD subjects according to GOLD classification (* $p = 0.001$; * $p = 0.048$).

Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; TB, tuberculosis.

Table 5 Cumulative mortality as on 31 December 2014 in the different groups of patients

Principal diagnosis on last discharge with mortality	All subjects (n=9,776)	GOLD 1 (n=85)	GOLD 2 (n=488)	GOLD 3 (n=808)	GOLD 4 (n=537)	No lung function coding (n=7,858)
Pneumonia	1,250 (32.3%)	8 (34.8%)	45 (28.1%)	76 (27.0%)	47 (19.3%)	1,074 (34.0%)
COPD	1,164 (30.1%)	3 (13%)	40 (25.0%)	92 (32.7%)	111 (45.7%)	918 (29.1%)
Lung cancer	243 (6.3%)	3 (13%)	18 (11.3%)	24 (8.5%)	8 (3.3%)	190 (6.0%)
Other malignancies	156 (4.0%)	0 (0%)	7 (4.4%)	6 (2.1%)	9 (3.7%)	134 (4.2%)
Respiratory failure	151 (3.9%)	0 (0%)	1 (0.6%)	20 (7.1%)	16 (6.6%)	115 (3.6%)
Ischemic heart disease	104 (2.7%)	0 (0%)	4 (2.5%)	8 (2.8%)	4 (1.6%)	88 (2.8%)
Sepsis and other systemic infections	102 (2.6%)	1 (4.3%)	8 (5.0%)	6 (2.1%)	4 (1.6%)	83 (2.6%)
Heart failure	71 (1.8%)	1 (4.3%)	5 (3.1%)	6 (2.1%)	4 (1.6%)	55 (1.7%)
Renal failure	40 (1.0%)	0 (0%)	1 (0.6%)	3 (1.1%)	2 (0.8%)	34 (1.1%)
Cerebrovascular accident	37 (1.0%)	0 (0%)	0 (0%)	4 (1.4%)	2 (0.8%)	31 (1.0%)
Others	549 (14.3%)	7 (30.4%)	31 (19.4%)	36 (12.1%)	36 (15.0%)	439 (13.9%)
All-cause mortality in HA hospital (%)	3,867/9,776 (39.6%)	23/85 (27.1%)	160/488 (32.8%)	281/808 (34.8%)	243/537 (45.3%)	3,160/7,858 (40.2%)
Death outside HA hospital (%)	560/9,776 (5.7%)	4/85 (4.7%)	23/488 (4.7%)	40/808 (5.0%)	34/537 (6.3%)	459/7,858 (5.8%)
Total mortality – in and outside HA hospital (%) [#]	4,427/9,776 (45.3%)	27/85 (31.8%)	183/488 (37.5%)	321/808 (39.7%)	277/537 (51.6%)	3,619/7,858 (46.1%)
Age at death, years; mean (SD), M, F [*] , [actual number of M & F patients with death]	M – 80.5 (8.4) [3,637]; F – 86.4 (7.7) [790]	M – 83.3 (9.9) [24]; F – 89.0 (7.3) [3]	M – 80.9 (7.1) [157]; F – 84.4 (6.7) [26]	M – 78.5 (7.5) [299]; F – 83.6 (5.1) [22]	M – 75.4 (7.9) [243]; F – 81.0 (8.4) [34]	M – 81.1 (8.4) [2,914]; F – 86.8 (7.6) [705]

Notes: ^{*}GOLD 1–2 vs GOLD 3–4, $p=0.002$; GOLD 1 vs GOLD 4, $p=0.002$; GOLD 2 vs GOLD 4, $p<0.0001$; GOLD 3 vs GOLD 4, $p<0.0001$; GOLD 1–4 vs no lung function, 42.1% vs 46.1%, $p=0.002$; [#]M: GOLD 1 vs GOLD 4, $p=0.005$; GOLD 2 vs GOLD 3, $p=0.005$; GOLD 2 vs GOLD 4, $p<0.0001$; GOLD 3 vs GOLD 4, $p<0.0001$; GOLD 1–2 vs GOLD 3–4, $p<0.0001$; GOLD 1–4 vs no lung function coding, $p<0.0001$; F: GOLD 1–4 vs no lung function coding, $p<0.0001$. Bold figures indicate statistically significant ($p<0.05$).

Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; HA, Hospital Authority; NS, not significant.

to the life expectancy of 81.3 years for men and 87.3 years for women in the general population of HK. There was an inverse relationship of GOLD class with the age at death. Patients with GOLD 4 disease had the lowest mean age at death of 75.4 years for men and 81.0 years for women. The difference was statistically significant for men but not for women, probably because of the smaller number of female patients. For patients without lung function coding, the mean age at death (M: 81.1 years, F: 86.8 years) was greater than that of those with lung function coding (M: 78.2 years, F: 83.0 years; $p < 0.0001$).

In total, 1,585 of 9,776 (16.2%) patients died in the HA hospitals in 2012, while 8,191 of 9,776 patients (83.8%) survived after their last discharge from the HA hospitals in 2012. Using the last discharge date from the HA hospitals in 2012 as the index date, the top 5 causes of death of these patients in the HA hospitals in 2012, at 1 year (1–365 days) after discharge and at 2 years (366–730 days) after discharge, are listed in Table 6. The top 5 causes of death in the HA hospitals were COPD, pneumonia, lung cancer, respiratory failure, and other malignancies with no significant variation observed over the 2-year period. The 1-year mortality rate after discharge in 2012 was 1,175/8,191 (14.3%); 1,245 patients died in the second year. The 2-year mortality rate was 2,420/8,191 (29.5%).

Discussion

The use of electronic medical record databases makes it possible to study large patient cohorts. Studies had been carried out with the UK Clinical Practice Research Datalink GOLD to study exacerbations in COPD patients in primary care.¹³ We have collected hospital admission data of a large COPD cohort using a computerized system (CDARS).^{10,11} To the best of our knowledge, this is the first study of this kind for COPD patients in HK. We have chosen to investigate the common parameters including demographic data, use of hospital services such as hospital stays, A&E attendance, use of NIV, and medication prescription in patients with different GOLD classes. These parameters provide important statistical figures for the estimation of disease burden and consumption of health care resources. In future, it is possible to extend the study to other parameters and make correlations between different subgroups. As most of the analytical work with CDARS can be performed with statistical manipulation, but without additional data entry, it is possible to repeat the study within a short period at low cost and have near real-time monitoring of the parameters of interest. It is also possible to track information and outcome of subgroups over time.

Table 6 Top 5 causes of in-hospital mortality in 2012 and at 1 year and 2 years of discharge from hospital

Mortality in and outside HA hospitals	Death within 2012		1 year after hospital discharge in 2012		2 years after hospital discharge in 2012	
	Number (%)	Number (%)	Number (%)	Number (%)	Number (%)	Number (%)
Top 5 causes of mortality in HA hospital (number, % of total mortality, in and outside HA hospitals)	1. COPD 2. Pneumonia 3. Lung cancer 4. Respiratory failure 5. Other malignancies	503 (31.7) 456 (28.8) 107 (6.8) 69 (4.4) 48 (3.0)	1. COPD 2. Pneumonia 3. Lung cancer 4. Other malignancies 5. Respiratory failure	303 (25.8) 282 (24.0) 66 (5.6) 37 (3.1) 31 (2.6)	1. Pneumonia 2. COPD 3. Lung cancer 4. Other malignancies 5. Respiratory failure	401 (32.2) 271 (21.8) 55 (4.4) 53 (4.3) 38 (3.1)
Total mortality in HA hospital (number)	1,585		831		1,092	
Death outside HA hospital (number)	0		344		153	
Total mortality (in and outside HA hospital) (number)	1,585		1,175		1,245	

Abbreviation: HA, Hospital Authority.

HK is a densely populated city with >7.3 million citizens. There are more women than men in HK with a male-to-female ratio of around 1:1.18. The expectation of life for men and women as in 2016 was 81.3 and 87.3 years, respectively (Census and Statistics Department, the Government of HK Special Administrative Region [HKSAR]).¹⁴ About 95% of the population depended on the HA for hospital service, which is heavily subsidized by the government. Free ambulance service is provided to patients in need in any area of the territory. The most significant “bottleneck” to hospital admission appears to be the availability of hospital beds, and only patients with more severe diseases could be admitted.

The present study included all except one regional acute general medical department and all except one chest hospital in HK in 2012–2014. We believed that the information obtained from this study would be a representative of the total picture of COPD admissions in HK. This study will help to provide information on the burden of COPD on the public hospital health care system, the case mix, and severity of COPD in HK and provide reference for resource and manpower allocation in the future. The information would probably also provide useful reference for other countries in Asia.

This study captured the data of 19,795 episodes of admissions with >9,000 patients admitted to public hospitals in HK with the principal diagnosis of COPD in 2012. We found that the majority of COPD patients were elderly men. The predominance of male patients may limit the generalization of our findings to female patients. Many patients were not using the appropriate medications as recommended by the GOLD guidelines.¹² In total, 61% of our patients had at least one of the comorbid illnesses (hypertension, ischemic heart disease, diabetes mellitus, old TB, bronchiectasis, congestive heart failure, and asthma).

Only about 20% of our patients had lung function coding entered in 2012. The lung function could have been performed in 2012 or earlier. The coding would also include the severity of COPD according to the ranges of the GOLD¹² stages once it was entered. The coding of lung function is not mandatory for the CMS in HA. The attending physician could choose not to code the lung function even if it had been performed. We expected the percentage of patients with lung function ever performed to be much >20%. Our previous pilot study with case record review¹⁰ showed that 64% of COPD patients admitted to hospital had at least one spirometry that was ever performed. It appeared from the present study (Table 2) that patients with more A&E attendance, hospitalizations, and clinic follow-ups were more

likely to have the spirometry coding entered by the attending physicians. It also appeared that the group with spirometry coding had more severe COPD and/or exacerbation as their hospital stay was longer (17.9 vs 11.0 days, $p<0.001$), and many more of them required NIV support (39.8% vs 19.3%, $p<0.001$) compared with patients without lung function coding. The group without lung function coding appeared to have less severe disease/exacerbation, but their mortality rate was paradoxically higher than that of the group with lung function coding (46.1% vs 42.1%, $p<0.002$). The mean ages at death of the group without lung function coding were 81.1 and 86.8 years for men and women, respectively, which were very close to the life expectancy for the general population (81.3 and 87.3 years, respectively). The higher mortality in this group could perhaps be explained by a natural course of disease toward the end of life.

A recent study in the USA found that about 70% of the participants of the surveys had undiagnosed COPD as revealed with spirometry. For those with airflow obstruction, their risk of death was increased compared with subjects without airflow obstruction.¹⁵ Another recent study found that airflow obstruction at the age of 55 years was an important risk factor for future COPD hospitalizations.¹⁶ Poor lung function has been associated with an increased risk of exacerbations. Previous studies had shown that exacerbations became more frequent and more severe as the severity of COPD increased.^{13,17,18} We have the same observation in this study in which those with poorer lung function had more admissions for COPD, more frequent need for NIV support, longer length of hospital stay as well as higher mortality.

Our data did not allow us to group the subjects according to the GOLD guideline¹²-recommended A, B, C, and D groups as we did not have the symptoms scores coding in the CMS. As all these subjects had at least one admission for COPD in 2012, they should all belong to group C or D according to the GOLD guideline¹² after their first admission to hospital in 2012. For subjects in GOLD group C or D, it is recommended that subjects should be on at least ICS + LABA and/or LAMA. However, we found that only 24% of our patients were given prescriptions according to this guideline after discharge from hospital. Recent published data from HK also showed that there was suboptimal adherence to GOLD guideline, and overprescription of ICS was identified.¹⁹ Optimization of the drug therapy would help to reduce the risk of developing acute exacerbation of COPD (AECOPD). Combination of ICS and LABA could lead to around a quarter fewer AECOPD than were seen with placebo.²⁰ Tiotropium can also reduce the odds of COPD

exacerbations (OR =0.74, 95% CI =0.66–0.83) and related hospitalizations (OR =0.64; 95% CI =0.51–0.82) compared with placebo or ipratropium.²¹

A recent study²² has shown that with the omission of spirometry in 2017 GOLD ABCD classification,²³ the revised system shifted many patients from C and D to A and B, possibly leading to reduced intensity of therapies. On the other hand, treatment with acute NIV for COPD admissions was more likely guided by the arterial blood gases. Our study showed that patients with GOLD 3 and 4 diseases were more likely to be treated with NIV than patients with GOLD 1 and 2 diseases. An earlier longitudinal study had also demonstrated that FEV₁ was one of the factors associated with mortality risk in COPD.²⁴ Patients with compensated and decompensated respiratory acidosis had poorer lung function and higher risk of death/life-threatening events compared with patients with normocapnia.²⁵ Exacerbations were also more common in patients with poorer lung function.^{13,17,18} Further studies are warranted to find out whether spirometry may have prognostic value in predicting the frequent exacerbators, development of type 2 respiratory failure, need of NIV, and mortality in patients with COPD.

Among the comorbidities, hypertension (40% of all subjects) was the commonest comorbidity followed by diabetes mellitus (15%) and cardiac diseases (congestive heart failure: 13.9%; and ischemic heart disease: 11.3%). A previous study²⁶ found that hypertension, hyperlipidemia, and coronary artery diseases are the 3 commonest comorbidities, and this was similar to the findings in the present study. Other comorbidities including anxiety/depression, heart failure, pulmonary hypertension, and metabolic syndrome had been reported.²⁷ Clinicians should screen their COPD patients for the presence of comorbidities for which specific treatments are available and are associated with better COPD outcomes.²⁸ Vascular comorbidities in COPD may have a direct impact on patient survival.²⁹ In total, 9.0% and 7.5% of our subjects had chronic effects of TB and bronchiectasis, respectively. Self-reported TB was a risk factor for COPD in nonsmokers.³⁰ A history of TB should be considered as a potentially important cause of obstructive lung disease, particularly where TB is common.³¹ HK has quite a high prevalence of TB (in 2015, total notifications of 4,498 cases with a notification rate of 61.63 per 100,000 population).³²

The all-cause mortality rate in the HA hospitals was 16.2% in 2012. This was much higher than the yearly mortality rate (4%–5%) in a study from the USA for AECOPD.³³ In this study, about 3% and 6% of the subjects required

NIV and IMV support, respectively. In total, 23.3% of our COPD patients required NIV support, but a much lower rate of IMV (1.4%). A previous study found that the assignment of do-not-resuscitate status was the most significant independent predictor of avoiding intubation (OR =0.11, 95% CI =0.03–0.37).³⁴ As we have not collected the data of do-not-resuscitate status, we were not sure if this could have contributed to the lower rate of IMV in our subjects.

On 31 December 2014 (after >2 years of discharge from hospital for the first episode of COPD in 2012), 4,427 (45.3%) of the original cohort of 9,776 patients had died (3,867 [39.6%] within the HA hospitals; Table 5). The high mortality in our group of patients was comparable to the previously reported high mortality of 22%–43% after 1 year and 36%–48% after 2 years following hospital admission reported from the USA, the Netherlands, and Spain.^{35–38} The high cumulative mortality in our group of patients could perhaps be explained by their relatively older age (mean age at death of 80 and 86 years for men and women, respectively) and the severity of their illness as reflected by the high percentage of patients requiring NIV. The availability of hospital beds precludes the admission of patients with milder disease, and only patients with more severe disease could be admitted. The lower denominator would increase the mortality rate in areas where bed availability is a problem.

A study conducted in Spain showed that the mortality rate was 35.6% at 2 years following hospital discharge for COPD; 50% of patients died from respiratory diseases and 19% from cardiovascular diseases.³⁷ An earlier single-center, prospective study in HK (243 COPD subjects) showed a mortality rate of 25% over 3 years.³⁹ The common causes of death were COPD (24.9%), pneumonia (6.6%), and lung cancer (13.1%). In our present study, the 2-year mortality rate after hospital discharge was 29.5% (Table 6). The top causes of death were similar – pneumonia, COPD, and lung cancer, but the percentages were somewhat different (32.2%, 21.8%, and 4.4% respectively), probably related to case selection in the earlier prospective study. Cardiovascular comorbidities were common in COPD patients in HK^{10,39} (Table 4; Figure 1 [in the present study]), but the incidence of cardiovascular deaths was disproportionately low in the present study (5.5%; Table 5) as well as in earlier studies in HK.^{10,39} It is possible that the cardiovascular symptoms were masked by the overwhelming respiratory events in our critically ill COPD patients. A significant proportion of the subjects might have died of cardiovascular or cerebrovascular diseases outside hospital.

Limitations

The potential limitations of this study were the following: some parameters requiring physician coding may be inaccurate and/or incomplete. Coding for COPD remains a physician-led diagnosis in HK, and unlike the UK system, lung function coding is not mandatory. Only about 20% of the subjects had coding for lung function. For the remaining patients, lung function might or might not be performed. The timing of lung function was also not available in the earlier version of the CMS. This information was recently incorporated in the latest version of the CMS, but manual capture of data is still required. These problems may be solved in future with automatic uploading of the spirometric data to the CMS. The Medical Research Council dyspnea grade and exacerbation rate (apart from the severe exacerbations resulting in hospital admissions) were not included in the present format of the CMS, and a low coding rate is expected even if they are included. Exploration of clinical or biochemical parameters (eg, PaO₂ and pCO₂) that do not require manual coding will assist in the development of computerized data collection and analysis for COPD in the future.

Conclusion

It is possible to collect and analyze data of a large COPD cohort using a computerized system. COPD is a disease with high morbidity and mortality. Most subjects were elders with recurrent hospital admissions, and NIV support was required in 23% of subjects. Many of them were not on optimal medical therapy for COPD. Pneumonia and COPD were common causes of mortality. Improved care of COPD patients by optimizing their pharmacological treatment and management of their comorbidities may improve outcomes. Palliative care could be planned in advance for patients with poor prognostic factors.

Acknowledgments

We would like to thank Ms Carrie Wong and Ms Reling Tse of Medial Records Office for generating the patient statistics from CDARS and Dr YL Cheng for his assistance in statistical analysis. We would also like to thank Dr Thomas Mok, Dr KS Lau, Dr KL Choo, Dr KK Chan, Dr CH Chau, Dr CM Chu, Dr ML Wong, Dr Wilson KS Yee, and Dr PY Tse who worked as coordinators for the hospitals involved in this study and the HK Lung Foundation for sponsoring this project.

Disclosure

The authors received no personal fee from any grant or commercial companies and report no other conflicts of interest in this work.

References

1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet*. 2007;370:741–750.
2. Ko FW, Hui DS, Lai CK. Worldwide burden of COPD in high- and low-income countries. Part III. Asia-Pacific studies. *Int J Tuberc Lung Dis*. 2008;12:713–717.
3. Ko FW, Woo J, Tam W, et al. Prevalence and risk factors of airflow obstruction in an elderly Chinese population. *Eur Respir J*. 2008;32:1472–1478.
4. Chan-Yeung M, Lai CK, Chan KS, et al. The burden of lung disease in Hong Kong: a report from the Hong Kong Thoracic Society. *Respirology*. 2008;13:S133–S165.
5. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2007;4: 502–506.
6. Darkow T, Kadlubek PJ, Shah H, Phillips AL, Marton JP. A retrospective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. *J Occup Environ Med*. 2007; 49:22–30.
7. Lau AC, Ip MS, Lai CK, et al. Variability of the prevalence of undiagnosed airflow obstruction in smokers using different diagnostic criteria. *Chest*. 2008;133:42–48.
8. Miravittles M, Murio C, Tirado-Conde G, et al. Geographic differences in clinical characteristics and management of COPD: the EPOCA study. *Int J Chron Obstruct Pulmon Dis*. 2008;3:803–814.
9. Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute exacerbations of COPD. *QJM*. 2010;103:817–829.
10. Au LH, Chan HS. Severity of airflow limitation, co-morbidities and management of chronic obstructive pulmonary disease patients acutely admitted to hospital. *Hong Kong Med J*. 2013;19:498–503.
11. Man LP, Ho AW, Wong SH. Excess mortality for operated geriatric hip fracture in Hong Kong. *Hong Kong Med J*. 2016;22:6–10.
12. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Updated 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf. Accessed April 7, 2016.
13. Mullerova H, Shukla A, Hawkins A, Quint J. Risk factors for acute exacerbation of COPD in a primary care population: a retrospective observational cohort study. *BMJ Open*. 2014;4:e006171.
14. Census and Statistics Department, The Government of the HKSAR. Available from: <http://www.censtatd.gov.hk>. Accessed February 10, 2018.
15. Martinez CH, Mannino DM, Jaimes FA, Curtis JL, Han MK, Hansel NN, Diaz AA. Undiagnosed obstructive lung disease in the United States. Associated factors and long-term mortality. *Ann Am Thorac Soc*. 2015; 12:1788–1795.
16. Zaigham S, Wollmer P, Engstrom G. Lung function, forced expiratory volume in 1 s decline and COPD hospitalisations over 44 years of follow-up. *Eur Respir J*. 2016;47:742–750.
17. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Eng J Med*. 2010;363: 1128–1138.
18. Calverley PM, Tetzlaff K, Dussler D, et al. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. *Int J Chron Obstruct Pulmon Dis*. 2017;12:3391–3405.

19. Chan KP, Ko FW, Chan HS, et al. Adherence to a COPD treatment guideline among patients in Hong Kong. *Int J Chron Obstruct Pulmon Dis*. 2017;12:3371–3379.
20. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2007;(4):CD006829.
21. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2005;(2):CD002876.
22. Tan WC, Bourbeau J, Aaron SD, et al. GOLD 2017 classification and lung function decline in chronic obstructive pulmonary disease. *Am J Resp Crit Care Med*. 2018;197(5):670–673.
23. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Updated 2017. Available from: <http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-COPD/>. Accessed November 22, 2017.
24. Terzano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. *Lung*. 2010;188:321–329.
25. Lun CT, Tsui MSN, Cheng SL, Chan VL, Leung WS, Cheung PS, Chu CM. Differences in baseline factors and survival between normocapnia, compensated respiratory acidosis and decompensated respiratory acidosis in COPD exacerbations: a pilot study. *Respirology*. 2016;21:128–136.
26. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2012;186:155–161.
27. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. *Int J Chron Obstruct Pulmon Dis*. 2014;9:871–888.
28. Brown JP, Martinez CH. Chronic obstructive pulmonary disease comorbidities. *Curr Opin Pulm Med*. 2016;22:113–118.
29. Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. *Eur Respir Rev*. 2013;22:454–475.
30. Lee SH, Hwang ED, Lim JE, et al. The risk factors and characteristics of COPD among nonsmokers in Korea: an analysis of KNHANES IV and V. *Lung*. 2016;194:353–361.
31. Amaral AF, Coton S, Kato B, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. *Eur Respir J*. 2015;46:1104–1112.
32. Center for Health Protection HKSAR. Tuberculosis notification. 2016. Available from: <http://www.chp.gov.hk/en/data/1/10/26/43/5104.html>. Accessed April 7, 2016.
33. Lima FV, Yen TYM, Patel JK. Trends in in-hospital outcomes among adults hospitalized with exacerbation of chronic obstructive pulmonary disease. *COPD*. 2015;12:636–642.
34. Digby GC, Keenan SP, Parker CM, et al. Noninvasive ventilation practice patterns for acute respiratory failure in Canadian tertiary care centres: a descriptive analysis. *Can Respir J*. 2015;22:331–340.
35. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. *Am J Respir Crit Care Med*. 1996;154:959–967.
36. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. *Chest*. 2003;124:459–467.
37. Amagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. *Chest*. 2002;121:1441–1448.
38. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax*. 2005;60:925–931.
39. Ko FW, Tam W, Tung AH, et al. A longitudinal study of serial BODE indices in predicting mortality and readmissions for COPD. *Respir Med*. 2011;105:266–273.

Supplementary material

List of hospitals included in the study

General hospitals

Alice Ho Miu Ling Nethersole Hospital, Caritas Medical Centre, Kwong Wah Hospital, North District Hospital, Pamela Youde Nethersole Eastern Hospital, Queen Elizabeth Hospital, Queen Mary Hospital, Prince of Wales Hospital,

Princess Margaret Hospital, the Ruttonjee and Tang Shiu Kin Hospital, Tseung Kwan O Hospital, Tuen Mun Hospital, and United Christian Hospital.

Chest hospitals

Grantham Hospital, Haven of Hope Hospital, and Kowloon Hospital.

International Journal of COPD

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress